EBITDA: Income before interest, taxes, depreciation and amortization.
Aldeyra Therapeutics, Inc. (ALDX) had EBITDA of $-6.65M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-6.46M |
|
-- |
|
-- |
|
$6.67M |
|
$-6.67M |
|
$0.21M |
|
$-6.46M |
|
$-6.46M |
|
$-6.46M |
|
$-6.46M |
|
$-6.46M |
|
$-6.46M |
|
$-6.67M |
|
|
EBITDA |
$-6.65M |
60.06M |
|
60.06M |
|
$-0.10 |
|
$-0.10 |
|
| Balance Sheet Financials | |
$71.78M |
|
-- |
|
$0.28M |
|
$72.06M |
|
$27.81M |
|
-- |
|
-- |
|
$27.81M |
|
$44.25M |
|
$44.25M |
|
$44.25M |
|
60.16M |
|
| Cash Flow Statement Financials | |
$-33.35M |
|
$47.74M |
|
$1.12M |
|
$54.53M |
|
$70.04M |
|
$15.51M |
|
$6.09M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.58 |
|
-- |
|
-- |
|
-- |
|
0.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-33.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.60% |
|
-14.60% |
|
-8.97% |
|
-14.60% |
|
$0.74 |
|
$-0.56 |
|
$-0.56 |
|